Two doses of parenterally administered split influenza virus vaccine elicited high serum IgG concentrations which effectively limited viral shedding upon challenge in mice

被引:27
作者
Hovden, AO [1 ]
Cox, RJ [1 ]
Madhun, A [1 ]
Haaheim, LR [1 ]
机构
[1] Univ Bergen, Gade Inst, Influenza Ctr, N-5021 Bergen, Norway
关键词
D O I
10.1111/j.1365-3083.2005.01666.x
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
We have previously found that whole influenza virus vaccine induced a more rapid and stronger humoral response, particularly after the first dose of vaccine, than split virus vaccine in mice. In this study, we have evaluated the protective efficacy of whole and split influenza virus vaccines in mice using a nonlethal upper respiratory tract challenge model. We have also investigated the immunological correlates associated with no or very little viral shedding after viral challenge. Vaccination resulted in reduced viral shedding and shortened the duration of infection by at least 2 days. After one dose of vaccine, whole virus vaccine generally resulted in less viral shedding than split virus vaccine. In contrast, two doses of split virus vaccine, particularly the highest vaccine strengths of 15 and 30 mu g HA, most effectively limited viral replication and these mice had high concentrations of prechallenge influenza-specific serum IgG. The vaccine formulation influenced the IgG2a/IgG1 ratio, and this IgG subclass profile was maintained upon challenge to some extent, although it did not influence the level of viral shedding. The concentration of postvaccination serum IgG showed an inverse relationship with the level of viral shedding after viral challenge. Therefore, serum IgG is an important factor in limiting viral replication in the upper respiratory tract upon challenge of an antigenically similar virus.
引用
收藏
页码:342 / 352
页数:11
相关论文
共 59 条
[1]  
[Anonymous], TXB INFLUENZA
[2]   Protection against influenza virus infection in polymeric Ig receptor knockout mice immunized intranasally with adjuvant-combined vaccines [J].
Asahi, Y ;
Yoshikawa, T ;
Watanabe, I ;
Iwasaki, T ;
Hasegawa, H ;
Sato, Y ;
Shimada, S ;
Nanno, M ;
Matsuoka, Y ;
Ohwaki, M ;
Iwakura, Y ;
Suzuki, Y ;
Aizawa, C ;
Sata, T ;
Kurata, T ;
Tamura, S .
JOURNAL OF IMMUNOLOGY, 2002, 168 (06) :2930-2938
[3]  
BACHMANN MF, 1994, J IMMUNOL, V153, P3386
[4]   COMPARATIVE TRIAL OF INFLUENZA VACCINES .1. IMMUNOGENICITY OF WHOLE VIRUS AND SPLIT PRODUCT VACCINES IN MAN [J].
BARRY, DW ;
MAYNER, RE ;
STATON, E ;
DUNLAP, RC ;
RASTOGI, SC ;
HANNAH, JE ;
BLACKBURN, RJ ;
NORTMAN, DF ;
GRAZE, PR .
AMERICAN JOURNAL OF EPIDEMIOLOGY, 1976, 104 (01) :34-46
[5]   Compromised influenza virus-specific CD8+-T-Cell memory in CD4+-T-cell-deficient mice [J].
Belz, GT ;
Wodarz, D ;
Diaz, G ;
Nowak, MA ;
Doherty, PC .
JOURNAL OF VIROLOGY, 2002, 76 (23) :12388-12393
[6]   Heterosubtypic immunity to influenza A virus in mice lacking IgA, all Ig, NKT cells, or γδ T cells [J].
Benton, KA ;
Misplon, JA ;
Lo, CY ;
Brutkiewicz, RR ;
Prasad, SA ;
Epstein, SL .
JOURNAL OF IMMUNOLOGY, 2001, 166 (12) :7437-7445
[7]   Immunoglobulin-A antibodies in upper airway secretions may inhibit intranasal influenza virus replication in mice but not protect against clinical illness [J].
Bizanov, G ;
Janakova, L ;
Knapstad, SE ;
Karlstad, T ;
Bakke, H ;
Haugen, IL ;
Haugan, A ;
Samdal, HH ;
Haneberg, B .
SCANDINAVIAN JOURNAL OF IMMUNOLOGY, 2005, 61 (06) :503-510
[8]   IGM AND IGG ANTIBODY-RESPONSES AFTER IMMUNIZATION OF CHILDREN WITH INACTIVATED MONO-VALENT (A-NEW-JERSEY-76) AND BIVALENT (A-NEW-JERSEY-76-A-VICTORIA-75) INFLUENZA-VIRUS VACCINES [J].
BOYER, KM ;
CHERRY, JD ;
WELLIVER, RC ;
DUDLEY, JP ;
DESEDATOUS, J ;
ZAHRADNIK, JM ;
KRAUSE, PJ ;
SPENCER, MJ ;
BRYSON, YJ ;
GARAKIAN, AJ .
JOURNAL OF INFECTIOUS DISEASES, 1977, 136 :S665-S671
[9]   Humoral and cell-mediated immunity to Vero cell-derived influenza vaccine [J].
Brühl, P ;
Kerschbaum, A ;
Kistner, O ;
Barrett, N ;
Dorner, F ;
Gerencer, M .
VACCINE, 2000, 19 (9-10) :1149-1158
[10]   RESISTANCE OF ADULTS TO CHALLENGE WITH INFLUENZA-A WILD-TYPE VIRUS AFTER RECEIVING LIVE OR INACTIVATED VIRUS-VACCINE [J].
CLEMENTS, ML ;
BETTS, RF ;
TIERNEY, EL ;
MURPHY, BR .
JOURNAL OF CLINICAL MICROBIOLOGY, 1986, 23 (01) :73-76